當前位置:BPS Bioscience Inc.>>CAR T-Cell Therapy Cell Lines>> 78556TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line
Anti-BCMA CAR /NFAT (Luciferase) Re
Anti-CD19 CAR / NFAT (Luciferase) R
This cell line is a knockout of TCR (T Cell Receptor). The TRAC (T-Cell Receptor Alpha Constant) and TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα/β chains were genetically removed by CRISPR/Cas9 genome editing from recombinant Jurkat cells stably expressing the firefly luciferase gene under the control of NFAT response elements.
This cell line has been functionally validated and does not respond to anti-CD3 agonist antibodies, as opposed to parental NFAT-Luciferase Reporter Jurkat cells (BPS Bioscience #60621).
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
請輸入賬號
請輸入密碼
請輸驗證碼
以上信息由企業(yè)自行提供,信息內容的真實性、準確性和合法性由相關企業(yè)負責,化工儀器網對此不承擔任何保證責任。
溫馨提示:為規(guī)避購買風險,建議您在購買產品前務必確認供應商資質及產品質量。